Turbine was founded to overcome the limitations of existing methods in identifying oncology treatments that truly benefit the patients who receive them by combining molecular biology and artificial intelligence. The company has developed and validated the Simulated Cell, a proprietary and cutting-edge platform that runs billions of simulations prior to ever initiating preclinical development guiding real-life experiments with invaluable biological insights. This improves the likelihood of success for truly novel therapies and allows existing assets to be optimally targeted to patients most likely to benefit from them. Simulations have already been validated from target discovery to patient stratification and life cycle management in collaborations with multiple big pharma companies. Turbine is now leveraging the Simulated Cell platform to develop its own stream of programs, pursuing multiple high unmet oncology needs. The company is also working with partners to extend its pipeline to various modalities and cancer mechanisms.
Király utca 26
Király utca 26
Last round 🔗 €20M
November 22, 2022.
November 22, 2022.
Key people 🧑🤝🧑
- Interpretable cell simulation: Pioneering an approach that combines simulation with machine learning, Turbine maps and models how thousands of signaling proteins interact - characterizing cellular-level cancer behavior and response or resistance to treatment. The platform enables the simulation of drug-like effects from compounds that may not exist yet, on cells potentially unavailable for lab-based testing, like those of high unmet need cancer patients.
- Find new drugs: Turbine's approach will potentially allow for prediction not only what works in cells, mice and people but more importantly - why and how. Continuous iterations of simulations and proprietary in vitro and in vivo experiments confirm predictions and progress Turbine's pipeline while simultaneously improving the underlying Simulated Cell.
- Rationalize the entire R&D process: Turbine's Simulated Cells can be used to run the equivalent of any preclinical or clinical protocol at computational speed and scale. Running millions of simulations before conducting the most promising wet experiments, Turbine's platform guides every step from target ID to clinical Proof of Concept.
MSD GHI looks forward to enabling acceleration of Turbine's growth and expansion. We believe Turbine's Simulated Cell has the potential to transform key aspects of the oncology drug discovery and development process, providing insight at scale that will shed light on even the most challenging biological mechanisms.
— David M. Rubin, Ph.D., Managing Director, MSD GHI Fund 🔗
While Mercia has a long track record of investing in companies using AI technologies for life sciences and healthcare, Turbine is one of our first investments in an AI platform designed to address historic challenges to drug development. Turbine's core technology is highly differentiated and already validated by early work with large pharma partners. We are excited to support Turbine as it advances the Simulated Cell, deepens our collective understanding of cancer biology, and makes drug development more efficient and more successful across the biopharma industry.
— Daniela Tsoneva, Investment Manager, VCT Funds at Mercia 🔗
Last update: June 4, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more